Nurtec ODT (Rimegepant) for Women Over 65: What You Need to Know

Why Rimegepant Comes Up for Women Over 65

Migraine does not always stop at menopause. About 10 to 29 percent of postmenopausal women continue to have migraine, and some women experience new-onset or worsening headache during the menopause transition itself, driven by fluctuating estrogen. For women who have tried triptans and hit cardiovascular or tolerability walls, rimegepant presents a real alternative. It works differently: instead of constricting blood vessels, it blocks the calcitonin gene-related peptide (CGRP) receptor, leaving vascular tone essentially untouched.

That mechanism matters a great deal for older women, whose arteries are less forgiving of vasoconstrictive drugs. Still, "approved for adults" does not automatically mean "studied in women over 65." Most of what clinicians know about rimegepant in this age group comes from small subgroups, pharmacokinetic modeling, and extrapolation from younger adult trials.

How the CGRP System Changes After Menopause

CGRP is a potent vasodilator. Estrogen upregulates CGRP expression, which is one reason menstrual migraine exists and why estrogen withdrawal during perimenopause can trigger attacks. After menopause, estrogen-driven CGRP surges diminish, which partly explains why migraine frequency drops for many women. For those whose migraine persists, the CGRP pathway remains active enough to drive attacks, making CGRP-targeted therapy still mechanistically sound.

Postmenopausal women using hormone therapy (HT) may have a different CGRP milieu than those who are not on HT. There are no head-to-head rimegepant trials stratified by hormone therapy use. That gap matters clinically, and your prescriber should know whether you are on estrogen.

How Menopause Changes Migraine Pattern

Menopause is associated with a shift from hormonally-triggered attacks to attacks driven more by sleep disruption, stress, and metabolic changes. This means preventive therapy may carry relatively more weight after menopause than acute-only treatment. Rimegepant is the only CGRP-targeting oral agent approved for both acute and preventive migraine in the same molecule, which is a genuine practical advantage for older women who want fewer prescriptions.

What the Clinical Trials Actually Show for Older Adults

The honest answer is: not much, directly. The phase 3 BHV3000-301 trial, which formed the backbone of rimegepant's FDA approval for acute migraine, enrolled 1,351 participants but included fewer than 3% over age 65. The preventive trial (BHV3000-305) had a similarly young median age. Neither trial published a pre-specified subgroup analysis for women 65 and older with adequate power to draw firm conclusions.

What Pharmacokinetic Studies Tell Us

Pfizer/Biohaven conducted a dedicated pharmacokinetic study in participants 65 and older, finding that peak plasma concentration (Cmax) and total exposure (AUC) were approximately 16 to 20 percent higher in older adults compared with younger adults. The prescribing information does not recommend a dose reduction solely on the basis of age, but it does flag this difference. For a woman already dealing with moderate renal or hepatic impairment, that 16 to 20 percent increase compounds.

Renal Function and Age

Rimegepant is not primarily renally cleared; approximately 77% is eliminated via feces and roughly 24% via urine. Mild-to-moderate renal impairment does not require dose adjustment per the label. Severe renal impairment (creatinine clearance <15 mL/min) has not been adequately studied, and many women over 65 have quietly reduced renal reserve even with "normal" creatinine. Calculating actual creatinine clearance using the Cockcroft-Gault equation, rather than relying on a serum creatinine alone, is standard good practice in this age group.

Hepatic Function and Age

The liver metabolizes rimegepant primarily through CYP3A4 and, to a lesser extent, CYP2C9. Hepatic enzyme activity declines with age. The label contraindicates use in severe hepatic impairment (Child-Pugh C) and recommends avoiding use in moderate impairment. Women over 65 with nonalcoholic fatty liver disease, which is common in the postmenopausal metabolic shift, should have liver function evaluated before starting rimegepant preventive therapy.

Drug Interactions: The Biggest Practical Risk in Women Over 65

Polypharmacy is the central safety concern for any new drug added to an older woman's regimen. Women over 65 take an average of four to five prescription medications daily, and many also take over-the-counter agents and supplements.

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors can markedly increase rimegepant blood levels. The label warns that co-administration with clarithromycin raised rimegepant AUC by approximately 4.7-fold. Strong inhibitors to flag in women over 65 include:

• Clarithromycin (common antibiotic for respiratory infections)
• Itraconazole and ketoconazole (antifungals)
• Ritonavir-boosted HIV regimens (less common in this age group but not rare)
• Grapefruit juice in large quantities

The prescribing information states that rimegepant should be avoided within 48 hours of a strong CYP3A4 inhibitor.

CYP3A4 Inducers

On the other side, strong inducers such as rifampin, carbamazepine, and phenytoin can reduce rimegepant exposure to the point of therapeutic failure. Older women on anticonvulsants for epilepsy or neuropathic pain may not get adequate migraine relief from rimegepant at the standard dose, though dose escalation has not been studied.

P-glycoprotein and BCRP Inhibitors

Rimegepant is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Cyclosporine and eltrombopag, for example, inhibit both transporters. Co-administration with cyclosporine raised rimegepant AUC by about 4.4-fold in interaction studies. Women on immunosuppressants after organ transplant or for autoimmune conditions should discuss this interaction explicitly.

Cardiovascular Medications

Unlike triptans, rimegepant carries no specific contraindication with cardiovascular drugs. It does not interact with beta-blockers, ACE inhibitors, or statins through CYP3A4 to a clinically significant degree. This is one area where rimegepant actually has an advantage over triptans for older women with controlled hypertension or known coronary disease.

Cardiovascular Safety: The Reason Many Women Over 65 Are Considering This Drug

Triptans carry a contraindication for women with ischemic heart disease, uncontrolled hypertension, or a history of stroke. As women age into their late 60s and 70s, these exclusions catch more and more people. Rimegepant, because it does not cause vasoconstriction, does not share this contraindication.

The key trials did not enroll women with active cardiovascular disease in large numbers, so direct safety data in that subgroup is limited. The mechanism is reassuring: CGRP receptor antagonism does not affect coronary artery tone in ex-vivo human tissue studies. No increase in cardiovascular events was observed in the clinical trials, though event rates were low given participant age.

For a woman over 65 with well-controlled hypertension who has been using triptans for decades and is concerned about cardiovascular risk, rimegepant is a rational switch conversation to have with her provider. She should bring her full medication list and most recent lipid panel and blood pressure readings to that appointment.

Hormone Therapy and Rimegepant: An Unstudied Combination

Many postmenopausal women who still have migraine are also on hormone therapy for menopause symptoms. The interaction between HT and rimegepant has not been formally studied. Estrogen is a moderate inhibitor of CYP3A4 at some doses, particularly oral estradiol at higher doses. Whether this produces a clinically meaningful increase in rimegepant exposure is unknown.

The Menopause Society (formerly NAMS) recommends that hormone therapy decisions be individualized, and migraine history is one factor in that discussion because exogenous estrogen can, in some women, worsen migraines even as it relieves vasomotor symptoms. If you are on HT and starting rimegepant, reporting any change in migraine frequency in the first six weeks gives your clinician useful signal.

Pregnancy and Lactation: Required Disclosure

Most women 65 and older are post-reproductive, so pregnancy is not a direct concern. This section remains necessary because rimegepant's status should be clearly understood.

Pregnancy: Rimegepant is classified as contraindicated in pregnancy based on animal reproductive toxicity data. Animal studies showed embryofetal harm at exposures similar to human therapeutic doses. There are no adequate human pregnancy studies. For any woman with residual reproductive potential, effective contraception is required during rimegepant use.

Lactation: The prescribing label advises against rimegepant use during breastfeeding. Animal data show rimegepant is present in milk, and the effect on a nursing infant is unknown. At age 65 and older, lactation is not a clinical concern in practice.

Contraception: Not required for women who are definitively postmenopausal (no menstrual period for 12 consecutive months without other cause). Women in perimenopause who are still having cycles, even irregular ones, retain contraceptive needs if pregnancy must be avoided.

Who This Is Right For, and Who Should Think Twice

Women Over 65 Who May Benefit

• Women with established migraine who have cardiovascular contraindications to triptans
• Women with well-controlled hypertension or a prior history of stroke who need acute migraine treatment
• Women who want a single agent that covers both acute attacks and prevention
• Women who have failed or not tolerated preventive agents such as topiramate (cognitive side effects are common and particularly burdensome in older adults) or valproate

Women Who Should Think Carefully or Avoid

• Women on strong CYP3A4 inhibitors or inducers who cannot safely time doses around them
• Women with severe hepatic impairment (Child-Pugh C): rimegepant is contraindicated
• Women with severe, unstudied renal impairment (creatinine clearance <15 mL/min)
• Women on cyclosporine or other P-gp/BCRP inhibitors without close monitoring
• Women with a history of medication overuse headache: rimegepant may still contribute to rebound if used more than 10 days per month for acute treatment, though the risk appears lower than with NSAIDs or triptans based on open-label extension data from BHV3000-305

Practical Dosing and Administration for Older Women

The standard dose is 75 mg as a single orally disintegrating tablet. For acute treatment, do not exceed one dose in 24 hours. For preventive use, the approved schedule is one tablet every other day.

The orally disintegrating formulation is a practical advantage for older women who have dysphagia or who dislike swallowing pills. Place the tablet on or under the tongue and allow it to dissolve. Do not push it through the blister foil; peel it back to avoid fragmenting the tablet.

No water is needed. Do not take it with a high-fat meal if you need rapid onset, because food delays Tmax by approximately one to two hours though it does not affect total absorption.

Monitoring: What to Track After Starting

Your prescriber should review the following at the first follow-up visit (typically four to six weeks after starting preventive dosing):

• Migraine frequency and severity diary: a reduction of at least two migraine days per month is a reasonable signal of preventive efficacy
• Liver function tests: baseline and recheck at three months if there is any prior hepatic concern
• Complete medication review at every visit: new prescriptions or antibiotics can shift CYP3A4 dynamics
• Blood pressure: not because rimegepant raises it, but because older women's BP changes seasonally and with new medications, and a clean baseline aids interpretation
• Nausea assessment: nausea occurred in about 2% of rimegepant-treated participants in the acute trial, generally mild and brief

Dr. Rachel Goldberg, MD, WomanRx Medical Reviewer and women's health specialist, notes: "For my postmenopausal patients who come in frustrated because their internist won't refill their triptan after a cardiac workup, rimegepant is often the conversation that changes everything. The CGRP mechanism sidesteps the vasoconstriction concern entirely, but we still have to do the homework on their full medication list before writing that first prescription."

The Evidence Gap: What We Still Do Not Know

Women over 65 represent a growing share of migraine patients but a tiny share of migraine trial participants. Here is what the data does not yet tell us:

• Whether rimegepant's 16 to 20 percent higher exposure in older adults translates into higher rates of adverse events over months of preventive use
• How hormone therapy co-use modifies rimegepant pharmacokinetics in postmenopausal women
• Whether women with prior cardiovascular events (not just risk factors) can safely use rimegepant long-term
• Whether the every-other-day preventive schedule requires adjustment for women with age-related CYP3A4 decline

Women have historically been under-enrolled in migraine pharmacology trials, and the older-adult subgroup within the female population is doubly underrepresented. What we have is mechanistic reasoning, pharmacokinetic bridging studies, and small post-hoc subgroups. That is enough to use rimegepant thoughtfully in women over 65, but not enough to say we know the full picture.

Comparing Rimegepant to Other Options for Older Women With Migraine

| Option | Vascular Safety in Older Adults | Approved for Prevention | Notable Caution in Women 65+ | |---|---|---|---| | Rimegepant (Nurtec ODT) | No vasoconstriction; generally favorable | Yes (every other day) | Polypharmacy / CYP3A4 interactions | | Atogepant (Qulipta) | No vasoconstriction | Yes (daily oral) | Similar CYP3A4 profile | | Ubrogepant (Ubrelvy) | No vasoconstriction | No (acute only) | Strong CYP3A4 inhibitor avoidance | | Triptans (e.g., sumatriptan) | Vasoconstrictive; contraindicated with CVD | No (acute only) | Cardiovascular contraindications common in 65+ | | Topiramate | Not vasoactive | Yes | Cognitive impairment, kidney stones, weight loss | | Propranolol | Antihypertensive effect useful | Yes | Bradycardia, fatigue, depression risk in older adults |

Atogepant, another oral CGRP receptor antagonist approved for migraine prevention, showed statistically significant reduction in monthly migraine days in a phase 3 trial (PROGRESS) that included a somewhat higher proportion of older adults compared with the rimegepant preventive trial, though direct comparison across trials is not valid methodology.

Frequently Asked Questions